Navigation Links
Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration

- Human Trials to Begin Later This Year

- Only Nasal Powder Bird Flu Vaccine Under Development

- Patient-Friendly (No Needles); No Preservatives

- Stable at Room Temperature For 3 Years; No Cold Chain Distribution


IRVING, Texas, Feb. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its wholly-owned subsidiary DelSite Biotechnologies, Inc. received a shipment of clinical-grade H5N1 (bird flu) antigen from a major pharmaceutical company to commence production, under cGMP requirements, of clinical quantities of DelSite's nasal powder bird flu (H5N1) vaccine. The nasal powder bird flu vaccine is scheduled to begin testing in a Phase I human clinical trial later this year.

The vaccine will utilize DelSite's proprietary GelVac(TM) nasal powder delivery platform, which offers many distinct advantages over traditional vaccine delivery systems: (1) easy, needle-free, self-administration, not requiring healthcare professionals; (2) enhanced protection because administration of vaccine into nasal cavity stimulates both a systemic response and mucosal response; (3) no adverse side effects caused by preservatives; (4) stability at room temperature, which eliminates the need for cold storage or cold chain distribution, thereby opening distribution to Third World countries where refrigeration is often not available; and, (5) a demonstrated shelf life of an influenza vaccine of three years, enabling potential stockpiling in the event of a pandemic.

As a prelude to the Phase I human trials, in January 2008 toxicology studies were successfully completed on a GelVac nasal powder (H5N1) influenza vaccine. The GelVac nasal powder platform has also successfully completed a Phase I safety study in which the delivery device provided a consistent, greater-than-90-percent delivery of the powder to the desired site in the nose.

Carlton E. Turner, PhD, Carrington's president and CEO, stated, "We are focusing our full attention on advancing DelSite's GelVac nasal powder delivery platform for vaccines and therapeutics, and the H5N1 bird flu antigen was selected specifically for this effort. We completed all toxicology studies last year and reported results in January 2008. Receiving the current shipment of the non-egg-based, clinical-grade bird flu antigen for human studies was the next step in our efforts. Our regulatory pathway has been determined with the FDA, and we intend to proceed with clarity of purpose to the Phase I safety and effectiveness human trial with the nasal powder bird flu vaccine later this year."

Dr. Turner added, "The success of Wyeth's Prevnar(R) pneumococcal vaccine and Merck's Gardasil(R) vaccine for cervical cancer has created a renewed interest in vaccines. According to a report by the Pharmaceutical Research and Manufacturers of America, more than 50 companies had 146 vaccines in various stages of development in 2007. Of these, 138 were classical liquid vaccines requiring needles, cold storage (2-8 degrees C), cold chain distribution (2-8 degrees C), and adjuvants and/or preservatives. Five were nasal mist vaccines with the same requirements except for needles, one was an influenza dermal patch, and two were powder formulations. Simply put, those requiring needles are not distributor- or user-friendly, and those requiring cold storage are not distributor- and may not be user-friendly."

"A simple, less expensive, easy-to-distribute, user-friendly delivery system would serve to complete the vaccine paradigm shift away from needles and cold storage/distribution as was started by FluMist(R), a liquid nasal spray flu vaccine," Dr. Turner added. "Dr. Nayer Khazani, a specialist in internal medicine who also does research and teaches at Stanford University Medical Center, wrote in an article (February 2, 2008) in the San Francisco Chronicle, stating that ' ... as delivery systems move from needles to patches and nasal powders, prevention (and even cure) may come without the sting.' His comments underscore our belief that the GelVac nasal powder platform developed by DelSite will complete this total paradigm shift and, clearly, without a sting."

"GelVac(TM) powder has been shown to work with and stabilize many antigens and protein and peptide therapeutics," continued Turner. "All formulations tested are stable at room temperature, require no needles, no preservatives, no cold storage and can be shipped anywhere free of the restrictive cold chain distribution systems associated with other vaccines. As a nasal powder, it is patient-friendly and does not require administration by a medical professional. No painful injection could mean greater public acceptance and thus public protection on a broader scale against specific diseases."

"At the corporate level, we are analyzing our business models and exploring strategies to move all our business units forward. We have invested more than $54 million in DelSite and have incurred financial losses over recent years. As a company we are dedicated to funding DelSite's initiatives and programs. The fact that a major pharma company has twice provided us, free of cost, a non-egg based H5N1 bird flu antigen produced under the restriction required for human use, indicates that much of the heavy lifting may be behind us."

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.

SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. Carrington Reports on ISO 9001:2000 Inspection
9. Carrington Reports Third Quarter 2007 Results
10. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
11. Carrington Settles Lawsuit, Sets Sights On Future
Post Your Comments:
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:2/22/2017)... Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a ... of innovative biopharmaceutical products for companion animals, will host a ... a.m. ET to discuss financial results from the fourth quarter ... Interested participants and investors may access the audio webcast ... ...
(Date:2/22/2017)... ... ... Park Systems , a leader in Atomic Force Microscopy (AFM) since ... attendees and Park customers on Feb. 27, 2017 from 12-2pm at Morton’s The Steakhouse ... The luncheon will feature a talk on Automated AFM for Small-Scale and Large-Scale Surface ...
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, ... a new report, Sensors for Robotics: Technologies, Markets and Forecasts ... ... Revenues ... "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force ...
Breaking Biology News(10 mins):